Autotelic Bio
Autotelic Bio is a South Korea-based clinical-stage biotechnology company developing antisense oligonucleotide (ASO) therapeutics and a Phase 3 fixed-dose combination drug (ATB-101) for hypertension and type 2 diabetes, licensing regional rights to global pharmaceutical partners rather than selling directly.
- Company typePrivate
- Founded2015
- HeadquartersCheongju, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Autotelic Bio does
Autotelic Bio Inc. (오토텔릭바이오 주식회사) is a South Korea-based clinical-stage biotechnology company founded in 2015 (rebranded from Autotelic Korea in 2018) and headquartered in Cheongju, with an R&D center in Yongin. The company is developing RNA-targeted therapeutics, with a primary focus on antisense oligonucleotide (ASO) drug candidates and a fixed-dose combination (FDC) product. Its pipeline spans oncology (ATB-301, ATB-320), CNS and neurodegenerative disease (ATB-810), dermatology (ATB-720), a pulmonary fibrosis small molecule (ATB-610), and a Phase 3 FDC for comorbid hypertension and type 2 diabetes (ATB-101, olmesartan + dapagliflozin).
The company's technical foundation rests on two proprietary platforms: ASODE™, an AI-assisted ASO discovery engine that uses deep learning to analyze 2D/3D mRNA folding structures and reduces candidate synthesis from thousands to roughly 100 sequences with a stated >10% success rate and a sub-3.5-month discovery cycle; and C-Duplex™, a brain delivery enhancement technology designed to improve ASO distribution into the CNS for ATB-810 in ALS and MS. ATB-101 composition patents are granted in six jurisdictions (Korea, USA, Japan, Russia, Mexico, Brazil), with an additional China application pending.
Autotelic Bio operates an asset-light, licensing-driven business model. It does not commercialize directly; instead, it secures regional licensing and technology transfer agreements with pharmaceutical partners (Aché in Brazil, Chinoin in Mexico, Jeil Pharmaceutical across Korea/China/Japan, Youngjin Pharmaceutical in Korea, Firson, plus CROs Dream CIS and Tigermed) in exchange for upfront fees, milestone payments, and sales-based royalties. It has raised approximately KRW 166 billion (Series A KRW 8B in Jan 2020, KRW 3B strategic in Aug 2020, Series B KRW 155B in Mar 2022) and is preparing for a KOSDAQ IPO with Kiwoom Securities as lead underwriter.
Autotelic Bio firmographics
Firmographics- Name
- Autotelic Bio
- Legal name
- 오토텔릭바이오 주식회사 (Autotelic Bio Inc.)
- Website
- https://autotelic.co.kr
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Autotelic Bio is a South Korea-based clinical-stage biotechnology company developing antisense oligonucleotide (ASO) therapeutics and a Phase 3 fixed-dose combination drug (ATB-101) for hypertension and type 2 diabetes, licensing regional rights to global pharmaceutical partners rather than selling directly.
- Ownership category
- akta.pro rank
Autotelic Bio industry classification
Industry- Product category
- Biopharmaceutical Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Autotelic Bio is headquartered
LocationHeadquarters
- HQ city
- Cheongju
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Autotelic Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing and Technology Transfer: Autotelic Bio generates revenue through upfront payments, milestone payments, and sales-based royalties from licensing agreements. The company has licensed ATB-101 to Aché (Brazil), Chinoin (Mexico), and others. Receives technology transfer milestone payments plus ongoing royalties.
- Government Grants and R&D Funding: The company receives government funding for R&D projects including Deep Tech Challenge Project (up to KRW 100 billion), KDDF projects, and Ministry of SMEs and Startups grants.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Autotelic Bio product offering
Product offeringCore offering
Autotelic Bio is a clinical-stage biotechnology company that discovers and develops antisense oligonucleotide (ASO) based RNA therapeutics and fixed-dose combination (FDC) drugs, with a pipeline spanning hypertension+diabetes (ATB-101), immuno-oncology (ATB-301, ATB-320), inflammatory skin diseases (ATB-720), neurodegenerative diseases (ATB-810), and idiopathic pulmonary fibrosis (ATB-610). The company monetizes its pipeline through regional out-licensing, technology transfer, and royalty agreements with global pharmaceutical partners, leveraging its proprietary ASODE™ AI discovery platform and C-Duplex™ brain delivery platform.
Product overview
Autotelic Bio is an RNA-based innovative drug development company specializing in antisense oligonucleotide (ASO) therapeutics. The company's portfolio consists of proprietary platform technologies (ASODE™ for AI-powered ASO discovery and C-Duplex™ for brain delivery) and multiple drug candidates targeting various therapeutic areas: ATB-101 (hypertension + diabetes fixed-dose combination in Phase 3), ATB-301 (TGF-β2 ASO + IL-2 immunotherapy for cancer), ATB-320 (dual-action ASO anticancer), ATB-720 (CHI3L1 ASO for skin diseases), ATB-810 (CHI3L1 ASO for neurodegenerative diseases using C-Duplex™ brain delivery), and ATB-610 (ALK5 inhibitor for IPF). The company focuses on CNS and rare incurable diseases while developing hybrid drugs that combine existing proven compounds with novel mechanisms.
Differentiator
Problem solved
Functional benefit
Products and services
- ATB-101 World's first fixed-dose combination therapy pairing olmesartan (an ARB antihypertensive) with dapagliflozin (an SGLT2 inhibitor) for simultaneous treatment of hypertension and type 2 diabetes in a single pill, designed to improve medication adherence in chronic comorbid patients; in Phase 3 clinical trials in Korea with composition patents secured in six countries (Korea, USA, Japan, Russia, Mexico, Brazil) and out-licensed to Aché (Brazil), Chinoin (Mexico), Jeil Pharmaceutical (Korea/China/Japan/US), and Youngjin Pharmaceutical (Korea).
- ATB-301 TGF-β2-targeting antisense oligonucleotide (trabedersen) combined with IL-2 for immuno-oncology, designed to inhibit TGF-β2 while activating T-cells; currently in Phase 1b clinical trials, with clinical trial IL-2 supply provided by Clinigen Group.
- ATB-320
Quantifiable outcome
- Rapid Discovery < 3.5 Months with >10% Success Rate
- +1 more outcomes
Companies that use Autotelic Bio
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Autotelic Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature2 records
Autotelic Bio partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Aché Laboratórios Farmacêuticos S.A.coreExclusive license and technology transfer agreement for ATB-101 in Brazil. Aché secured manufacturing and commercialization rights. Autotelic Bio receives technology transfer milestone payments and sales-based royalties. Aché is a leading Brazilian pharmaceutical company with 50+ years history and 300+ brands.
- Chinoin Productos FarmaceuticoscoreExclusive license and supply agreement for ATB-101 in Mexico. 5-year agreement for 30 million+ tablets supply. Autotelic Bio receives upfront payment and milestone payments. Chinoin is a top 10 Mexican pharmaceutical company established in 1924.
- Dream CISminorMOU for global new drug development of ATB-101 and strategic investment. Global CRO for clinical development support.
- Youngjin PharmaceuticalcoreCo-development and technical implementation agreement for ATB-101. Youngjin participates in Phase 3 clinical trials and gains non-exclusive Korean sales rights. Autotelic Bio receives upfront fee, milestone payments, and sales royalties.
- FirsonminorJoint development contract for ATB-101. Firson cooperates with Autotelic Bio for product commercialization and receives sales royalties.
- Clinigen GroupminorAgreement for clinical trial supply of Proleukin (IL-2) for ATB-301 clinical studies. Clinigen supplies interleukin-2 product for Autotelic Bio's immunotherapy trials.
- ST PharmminorManufacturing supply agreement for Trabedersen (ATB-301). ST Pharm produces oligonucleotide clinical samples with GMP facilities. ST Pharm is ranked 3rd globally in oligonucleotide production and the only Korean company with cGMP oligonucleotide facilities.
- Jeil PharmaceuticalcoreJoint development and technology transfer agreement for ATB-101. Jeil secured exclusive rights for Korea, China, Japan and manufacturing rights for US market. Autotelic Bio received upfront and milestone payments totaling KRW 22 billion with ~KRW 200 billion total deal value including royalties.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Autotelic Bio competitors and assessment
Company assessmentRegional players
- Helixmith: Korean clinical-stage biotech developing gene therapies and biologics for neuropathy and rare diseases. Comparable on Korean-listed clinical-stage profile, late-stage clinical execution, and biologics modality.
- LigaChem Biosciences: Korean clinical-stage biotech focused on antibody-drug conjugates and immuno-oncology. Comparable on geography, therapeutic area overlap (oncology), and Korea KOSDAQ-listed clinical biotech profile.
Direct peers
- OliX Pharmaceuticals: Korean clinical-stage biotech developing RNAi/ASO therapeutics for skin, fibrotic, and ophthalmic diseases — the most direct comparable in geography, modality (oligonucleotide therapeutics), and development stage.
- Wave Life Sciences: Clinical-stage ASO company with PRISM platform targeting CNS and rare diseases including ALS and Huntington's — direct modality and indication overlap with Autotelic's ATB-810 program.
- Stoke Therapeutics: Clinical-stage company using ASOs to upregulate protein expression for severe genetic CNS diseases (Dravet, ADOA). Comparable on modality and CNS focus, with a similar early-to-mid clinical development profile.
Broad incumbents
- Ionis Pharmaceuticals: Global ASO leader with Spinraza, Tegsedi, and Wainua commercialized and 40+ pipeline programs. Most directly comparable on core modality (ASO therapeutics) and platform-driven pipeline generation, though materially larger and commercial-stage.
- Sarepta Therapeutics: Commercial-stage RNA therapeutics company with PMO and siRNA platforms for Duchenne muscular dystrophy and other neuromuscular diseases — comparable modality with much greater scale and commercialization.
- Alnylam Pharmaceuticals: Global RNAi therapeutics leader (Onpattro, Givlaari, Oxlumo, Amvuttra commercialized) with CNS-pipeline expansion. Comparable on RNA-based modality and platform-driven pipeline, with established commercialization.
- Biogen: Commercial-stage biotech with Spinraza (the first FDA-approved ASO for SMA) and broad CNS/neurodegeneration pipeline. Most comparable to Autotelic's CNS ASO ambitions via the C-Duplex platform and ATB-810.
Emerging players
- ProQR Therapeutics: Clinical-stage RNA editing company developing Axiomer platform-based ASOs for rare genetic diseases including CNS indications. Comparable on modality (ASO) and CNS/rare disease focus with similar pre-commercial stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Autotelic Bio social profiles
Digital presenceAutotelic Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Autotelic Bio leadership team
Management profileNumber of profiles
Profiles7 records
Autotelic Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Autotelic Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Autotelic Bio
What does Autotelic Bio do?
Autotelic Bio is a clinical-stage biotechnology company that discovers and develops antisense oligonucleotide (ASO) based RNA therapeutics and fixed-dose combination (FDC) drugs, with a pipeline spanning hypertension+diabetes (ATB-101), immuno-oncology (ATB-301, ATB-320), inflammatory skin diseases (ATB-720), neurodegenerative diseases (ATB-810), and idiopathic pulmonary fibrosis (ATB-610). The company monetizes its pipeline through regional out-licensing, technology transfer, and royalty agreements with global pharmaceutical partners, leveraging its proprietary ASODE™ AI discovery platform and C-Duplex™ brain delivery platform.
Is Autotelic Bio a public or private company?
Autotelic Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Autotelic Bio founded?
Autotelic Bio was founded in 2015. It employs 11 to 50 people.
Where is Autotelic Bio based?
Autotelic Bio is headquartered in Cheongju, South Korea, in the Asia region.
How does Autotelic Bio make money?
Two revenue lines are on record. Licensing and Technology Transfer is the primary driver. The others are government Grants and R&D Funding.
Who are Autotelic Bio's main competitors?
Regional players on record are Helixmith and LigaChem Biosciences. Direct peers are OliX Pharmaceuticals, Wave Life Sciences and Stoke Therapeutics. Broad incumbents are Ionis Pharmaceuticals, Sarepta Therapeutics, Alnylam Pharmaceuticals and Biogen. ProQR Therapeutics is listed as an emerging player.
Does Autotelic Bio have an API?
No public API is recorded for Autotelic Bio.
What industry is Autotelic Bio in?
Autotelic Bio's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.